Welcome to our dedicated page for MDB Capital Holdings LLC-A SEC filings (Ticker: MDBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the story behind MDB Capital Holdings� public-venture engine often means digging through hundreds of pages that blend investment-banking footnotes with patent analytics. If you are asking, “How do I read the MDB Capital Holdings annual report 10-K simplified?� or searching for “MDB Capital Holdings insider trading Form 4 transactions,� this page is built for you.
Stock Titan pairs every fresh 10-K, 10-Q, 8-K and proxy statement with AI-powered summaries that explain, in plain language, where underwriting fees show up, how the technology-development arm is funded, and which patents moved. Our platform delivers real-time Form 4 insider transactions, so you can track executive stock moves the moment they hit EDGAR. Need the latest “MDB Capital Holdings quarterly earnings report 10-Q filing� or want “MDB Capital Holdings 8-K material events explained�? One click surfaces key numbers, material agreements, and patent-portfolio milestones without combing line by line.
Every filing type connects directly to what drives MDBH’s value: 10-K segment notes reveal broker-dealer revenue versus licensing income; 10-Q cash-flow tables expose runway for new deep-tech launches; Form 4 data highlights when principals buy ahead of a spin-out; the proxy statement details executive compensation tied to successful early IPOs. Whether you’re screening “MDB Capital Holdings executive stock transactions Form 4,� comparing fee trends quarter-over-quarter, or simply “understanding MDB Capital Holdings SEC documents with AI,� Stock Titan keeps you ahead with concise analysis, historical archives, and instant alerts.
MDB Capital Holdings, LLC (Ticker: MDBH) filed a Form 4 for insider Christopher A. Marlett, the company’s co-founder, director, and 10% owner. The filing discloses three open-market purchases of Class A common stock executed on 24-26 June 2025.
- 24 Jun 2025: 20 shares purchased at an average price of $4.46 (multiple trades between $4.35-$4.50).
- 25 Jun 2025: 2 shares purchased at $4.50.
- 26 Jun 2025: 22 shares purchased at $4.50.
The total of 44 shares acquired increases Marlett’s indirect holdings—held as custodian for a minor—to 144,279 shares. All transactions were coded “P� (open-market purchases); no derivatives were reported. Ownership remains classified as indirect (“I�) and custodial (“CUST�).
No Rule 10b5-1 trading plan is indicated, and the filing does not reference any accompanying derivative activity or larger strategic transaction. The purchases represent a 0.03 % increase in Marlett’s disclosed position and do not materially alter overall share structure, but insider buying—however small—can be interpreted as a vote of confidence. Given the limited volume and dollar value (� $200), the market impact is expected to be minimal.
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) filed a Current Report on Form 8-K disclosing the formal voting results from its 16 June 2025 Annual Meeting of Shareholders.
- Election of directors: All six nominees—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins and Dina Katabi—were re-elected, each receiving roughly 1.32�1.34 million votes FOR versus 63�73 thousand AGAINST; 743,285 broker non-votes were recorded.
- Auditor ratification: Ernst & Young LLP was confirmed for fiscal 2025 with 2,072,684 FOR, 57,547 AGAINST and 147 ABSTAIN.
- Say-on-pay (advisory): Executive compensation passed (1,312,697 FOR; 78,221 AGAINST; 6,203 ABSTAIN).
- Say-on-pay frequency: Shareholders favored an annual vote (827,809 one-year vs. 562,965 three-year).
- Adjournment authority: The option to adjourn, if necessary, also passed (2,036,703 FOR; 84,719 AGAINST; 18,984 ABSTAIN).
The filing is procedural, reinforces existing governance structures and contains no new financial, operational or strategic disclosures likely to affect the company’s near-term outlook.
MDB Capital Holdings, LLC (MDBH) � Form 4 insider transaction
On 18 June 2025, co-founder, director, officer and 10 % owner Christopher A. Marlett reported an open-market purchase (Code P) of 635 Class A common shares at a weighted-average price of $4.04 per share (individual trades ranged from $4.00 to $4.06). The shares are held indirectly as custodian for a minor. Following the trade, Marlett’s indirect beneficial ownership increased to 142,670 shares. No derivative securities were involved and no dispositions were reported.
The filing is a routine Section 16 disclosure; the dollar value of the purchase is approximately $2,560 and represents less than 1 % of Marlett’s reported holdings.